Generic Lamictal XR® Launches

On January 18, 2013, Par Pharmaceuticals received final FDA approval and commenced shipping the AB-rated generic equivalent for GlaxoSmithKline’s branded product, Lamictal XR® (lamotrigine) tablets. Lamictal XR® had estimated total U.S. annual sales of approximately $262 million.

Lamictal XR is an antiepileptic indicated as adjunctive therapy for primary generalized tonic-clonic seizures or partial onset seizures with or without secondary generalization in patients older than 13 years of age, as well as for conversion to monotherapy in patients older than 13 years of age with partial seizures who are receiving treatment with a single antiepileptic drug.